By Adria Calatayud
Sanofi, the French pharmaceutical giant, is set to release its second quarter results on Friday. Here are the key details:
Sales Forecast
Analysts anticipate that Sanofi will report net sales of €10.04 billion ($11.13 billion) for the second quarter, based on consensus estimates compiled by Vara Research. This would be slightly lower than the net sales of €10.12 billion recorded during the same period last year.
Business Net Profit Forecast
The quarterly business net profit for Sanofi is expected to be around €2.09 billion, according to the Vara consensus. In comparison, the business net profit for the second quarter of the previous year amounted to €2.17 billion.
What to Watch
Guidance: Sanofi has provided guidance that its business earnings per share will grow by low single percentage digits at constant currency rates by 2023. A recent research note from JPMorgan suggests that the company’s guidance may be revised upward, although this is already factored into consensus expectations.
Dupixent: Market analysts at Jefferies highlight that the U.S. prescription growth for Sanofi’s popular anti-inflammatory drug, Dupixent (developed in partnership with Regeneron Pharmaceuticals), continues to thrive. Sanofi has projected Dupixent sales to reach €10 billion this year. Analysts polled by FactSet expect second quarter revenue from Dupixent to jump by 30% to €2.55 billion.
